Biolase Inc.
| NASDAQ: BIOL | Healthcare / Medical Devices & Instruments / USA |
| 1.11 | -0.0400 | -3.48% | Vol 86.12K | 1Y Perf 17.35% |
| Nov 29th, 2023 15:59 DELAYED |
| BID | 1.10 | ASK | 1.14 | ||
| Open | 1.20 | Previous Close | 1.15 | ||
| Pre-Market | - | After-Market | 1.11 | ||
| - - | - -% |
| Target Price | 14.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 1.16K | Finscreener Ranking | ★★★+ 51.38 | |
| Insiders Trans % 3/6/12 mo. | -/-/33 | Value Ranking | ★★ 45.52 | |
| Insiders Value % 3/6/12 mo. | -/-/85 | Growth Ranking | + 32.12 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/81 | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.04 | Earnings Rating | Buy | |
| Market Cap | 2.55M | Earnings Date | 9th Nov 2023 | |
| Alpha | -0.08 | Standard Deviation | 0.34 | |
| Beta | 1.34 |
Today's Price Range 1.101.20 | 52W Range 1.07104.00 | 5 Year PE Ratio Range -1.10-1.20 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -9.02% | ||
| 1 Month | -34.71% | ||
| 3 Months | -74.77% | ||
| 6 Months | 1 221.43% | ||
| 1 Year | 17.35% | ||
| 3 Years | 268.89% | ||
| 5 Years | -3.48% | ||
| 10 Years | -87.53% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -92.63 | |||
ROE last 12 Months | -122.83 | |||
ROA (5Y Avg) | -24.19 | |||
ROA last 12 Months | -52.51 | |||
ROC (5Y Avg) | -66.32 | |||
ROC last 12 Months | -62.31 | |||
Return on invested Capital Q | -24.42 | |||
Return on invested Capital Y | -11.38 | |||
Assets Turnover | 0.80 | |||
Receivables Turnover | 8.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.20 | ||||
| 0.37 | ||||
| 0.16 | ||||
| - | ||||
| -0.20 | ||||
| -3.72 | ||||
| 0.47 | ||||
| 1.94 | ||||
| 10.06M | ||||
| Forward PE | -12.39 | |||
| PEG | -0.18 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.10 | ||||
| 2.50 | ||||
| 0.51 | ||||
| 1.07 | ||||
| -12.40 | ||||
| Leverage Ratio | 2.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 36.80 | ||||
| -47.40 | ||||
| -46.30 | ||||
| -49.30 | ||||
| -54.56 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 34.41M | ||||
| 4.46 | ||||
| -5.14 | ||||
| -8.50 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -8.93 | - |
| Q01 2023 | - | -0.18 | - |
| Q03 2022 | - | -1.10 | - |
| Q02 2022 | - | -0.91 | - |
| Q01 2022 | - | -0.81 | - |
| Q04 2021 | -0.75 | -0.75 | 0.00 |
| Q03 2021 | -0.75 | -0.50 | 33.33 |
| Q02 2021 | -1.00 | -0.50 | 50.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2019 QR | -0.21 | 0.00 | - |
| 3/2022 QR | -0.03 | 70.00 | Positive |
| 12/2022 FY | -0.10 | - | - |
| 12/2022 FY | -0.10 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 86.12K |
| Shares Outstanding | 2.30K |
| Shares Float | 2.30M |
| Trades Count | 518 |
| Dollar Volume | 97.18K |
| Avg. Volume | 273.89K |
| Avg. Weekly Volume | 58.96K |
| Avg. Monthly Volume | 456.09K |
| Avg. Quarterly Volume | 306.62K |
Biolase Inc. (NASDAQ: BIOL) stock closed at 1.11 per share at the end of the most recent trading day (a -3.48% change compared to the prior day closing price) with a volume of 86.12K shares and market capitalization of 2.55M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 157 people. Biolase Inc. CEO is John R. Beaver.
The one-year performance of Biolase Inc. stock is 17.35%, while year-to-date (YTD) performance is 70.77%. BIOL stock has a five-year performance of -3.48%. Its 52-week range is between 1.07 and 104, which gives BIOL stock a 52-week price range ratio of 0.04%
Biolase Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.37, a price-to-sale (PS) ratio of 0.16, a price to cashflow ratio of -, a PEG ratio of -0.18, a ROA of -52.51%, a ROC of -62.31% and a ROE of -122.83%. The company’s profit margin is -54.56%, its EBITDA margin is -46.30%, and its revenue ttm is $34.41 Million , which makes it $4.46 revenue per share.
Of the last four earnings reports from Biolase Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biolase Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Biolase Inc. is Strong Buy (1), with a target price of $14, which is +1 161.26% compared to the current price. The earnings rating for Biolase Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biolase Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biolase Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 34.66, ATR14 : 0.13, CCI20 : -75.91, Chaikin Money Flow : -0.64, MACD : -0.18, Money Flow Index : 3.99, ROC : -22.03, RSI : 26.49, STOCH (14,3) : 10.39, STOCH RSI : 0.00, UO : 40.51, Williams %R : -89.61), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biolase Inc. in the last 12-months were: Jonathan T. Lord (Sold 3 537 shares of value $2 653 )
Biolase Inc.
Biolase Inc is a US-based medical device company. It develops, manufactures, markets and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products i.e. Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
CEO: John R. Beaver
Telephone: +1 949 361-1200
Address: 4 Cromwell, Irvine 92618, CA, US
Number of employees: 157
